Literature DB >> 15015571

CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma.

Daniela Mihic-Probst1, Jianming Zhao, Parvin Saremaslani, Angela Baer, Christian Oehlschlegel, Bruno Paredes, Paul Komminoth, Philipp U Heitz.   

Abstract

BACKGROUND: Atypical fibroxanthoma (AFX) and undifferentiated high grade pleomorphic sarcoma (UpS) are histologically very similar, if not identical. However, they differ significantly in clinical outcome.
MATERIALS AND METHODS: We used comparative genomic hybridization (CGH) to screen 24 AFX and 12 UpS for genomic alterations.
RESULTS: DNA copy number changes were observed in 20/24 AFX and in all UpS. The most frequent alterations occurring with comparable frequency in both tumors were deletions on chromosomes 9p and 13q. We also detected statistically significant differences of genetic alterations between the two tumors concerning deletions on 1q, 3p, 5q, 11p, 11q, gains on 7q, 12q and high level gains on 5p and 11q.
CONCLUSION: Despite their very similar histology, AFX and UpS show clear differences in their genetic alterations. This might contribute to the different biological behavior of the two tumors. On the other hand the similarities in genetic alterations on chromosomes 9p and 13q might suggest a common pathogenetic pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015571

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.

Authors:  Klaus G Griewank; Thomas Wiesner; Rajmohan Murali; Carina Pischler; Hansgeorg Müller; Christian Koelsche; Inga Möller; Cindy Franklin; Ioana Cosgarea; Antje Sucker; Dirk Schadendorf; Jörg Schaller; Susanne Horn; Thomas Brenn; Thomas Mentzel
Journal:  Mod Pathol       Date:  2017-11-03       Impact factor: 7.842

2.  Atypical fibroxanthoma.

Authors:  Akio Sakamoto
Journal:  Clin Med Oncol       Date:  2008-02-09

3.  Genomic analysis of atypical fibroxanthoma.

Authors:  Kevin Lai; Catherine A Harwood; Karin J Purdie; Charlotte M Proby; Irene M Leigh; Namita Ravi; Thaddeus W Mully; Lionel Brooks; Priscilla M Sandoval; Michael D Rosenblum; Sarah T Arron
Journal:  PLoS One       Date:  2017-11-15       Impact factor: 3.240

4.  Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas.

Authors:  Doris Helbig; Alexander Quaas; Cornelia Mauch; Sabine Merkelbach-Bruse; Reinhard Büttner; Michael Emberger; Marion Wobser; Vanessa Rüsseler; Katharina Pütz; Elke Binot; Jan Rehker; Jan Budczies; Michaela Angelika Ihle
Journal:  Oncotarget       Date:  2017-11-25

Review 5.  A Multidisciplinary Approach to Complex Dermal Sarcomas Ensures an Optimal Clinical Outcome.

Authors:  Hannah Trøstrup; Amir K Bigdeli; Christina Krogerus; Ulrich Kneser; Grethe Schmidt; Volker J Schmidt
Journal:  Cancers (Basel)       Date:  2022-03-26       Impact factor: 6.639

6.  Undifferentiated pleomorphic sarcoma in oropharyngeal mucosa of patients with multiple basal cell carcinomas.

Authors:  Andrea Dekanić; Marko Velepič; Margita Belušić Gobić; Ita Hadžisejdić; Nives Jonjić
Journal:  Rare Tumors       Date:  2021-06-30

7.  MYC gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma.

Authors:  Timo Gaiser; Daniela Hirsch; Azadeh Orouji; Marisa Bach; Peter Kind; Doris Helbig; Alexander Quaas; Jochen Utikal; Alexander Marx; Maria Rita Gaiser
Journal:  Oncotarget       Date:  2018-04-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.